Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Development of Immunocompetence01:22

Development of Immunocompetence

1.0K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis.

The Journal of allergy and clinical immunology·2026
Same author

Additive effects of common and rare genetic variants on inflammatory bowel disease risk in a cohort with immunodeficiency.

The Journal of allergy and clinical immunology·2026
Same author

IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Implementation of a Pilot Study in Adolescent Health Care Transition Program for Chronic Granulomatous Disease: A Single Institution Experience.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners·2024
Same author

Severe clinical phenotypes of heterozygous females with X-linked chronic granulomatous disease.

The journal of allergy and clinical immunology. In practice·2024
Same author

Human papillomavirus disease in <i>GATA2</i> deficiency: a genetic predisposition to HPV-associated female anogenital malignancy.

Frontiers in immunology·2024

Related Experiment Video

Updated: Feb 23, 2026

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR
14:14

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR

Published on: December 6, 2014

17.4K

Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.

Beatriz E Marciano1, Steven M Holland1

  • 1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.

Frontiers in Immunology
|August 30, 2017
PubMed
Summary

Primary immunodeficiency diseases (PIDs) stem from genetic defects, but new therapies are transforming patient outcomes. Advances in genetics and biologic modifiers offer novel treatments, improving life expectancy and quality of life for those affected.

Keywords:
chronic granulomatous diseaseimmune modulationimmunodeficiencyinterferon gammaleukocyte adhesion deficiency

More Related Videos

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.7K
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

24.0K

Related Experiment Videos

Last Updated: Feb 23, 2026

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR
14:14

Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR

Published on: December 6, 2014

17.4K
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.7K
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

24.0K

Area of Science:

  • Immunology
  • Genetics
  • Clinical Medicine

Background:

  • Primary immunodeficiency diseases (PIDs) arise from genetic defects impacting immune function.
  • Historically, treatments were primarily supportive, with bone marrow transplantation as a key exception.
  • Recent breakthroughs in immunobiology and genetics have revolutionized PID management.

Purpose of the Study:

  • To review the evolving landscape of primary immunodeficiency diseases.
  • To highlight the impact of recent advances on therapeutic options and patient outcomes.
  • To discuss the emergence of new conditions and targeted therapies for PIDs.

Main Methods:

  • Review of recent literature on immunobiology and genetics.
  • Analysis of advancements in biologic modifiers and targeted therapies.
  • Examination of trends in PID patient care, including infection and autoimmune management.

Main Results:

  • Significant improvements in therapeutic options and life expectancy for PID patients.
  • Identification of hundreds of new genetic causes of immune dysfunction through genomic research.
  • Emergence of targeted therapies and immunomodulatory agents as viable treatment strategies.

Conclusions:

  • Therapeutic strategies for PIDs have dramatically improved due to scientific advancements.
  • Genomic discoveries are paving the way for personalized and targeted treatments.
  • Increased longevity in PID patients reveals new challenges, including malignancies and degenerative disorders.